KRAS mutational status and efficacy in KEYNOTE-189: Pembrolizumab (pembro) plus chemotherapy (chemo) vs placebo plus chemo as first-line therapy for metastatic non-squamous NSCLC

著者: Shirish M. Gadgeel, Delvys Rodríguez‐Abreu, Enriqueta Felip, Emilio Esteban, G. Speranza, Martin Reck, Rina Hui, Michael Boyer, Edward B. Garon, Hidehito Horinouchi, Răzvan Cristescu, Deepti Aurora-Garg, Jared Lunceford, Julie Kobie, Mark Ayers, Bilal Piperdi, M. Catherine Pietanza, Marina Chiara Garassino - Annals of Oncology 2019 被引用: 82